The article you requested is
ASCP Corner: Are Nutritional Supplements Ready for Prime Time?
J Clin Psychiatry 2008;69:1497-1498
Copyright 2008 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Over the past 20 years, there has been a surge of clinical trials
examining the safety and efficacy of natural compounds for
psychiatric indications. These studies have produced encouraging
evidence for several putative antidepressants such as
S-adenosyl-L-methionine (SAMe), St. John’s wort (SJW), the
omega-3 fatty acids, and folic acid.
There are about 45 published randomized controlled trials
(RCTs) of SAMe monotherapy against placebo or tricyclic antidepressants